These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12007646)

  • 41. Toll-like receptor 2 (TLR2) plays a role in controlling cutaneous leishmaniasis in vivo, but does not require activation by parasite lipophosphoglycan.
    Halliday A; Bates PA; Chance ML; Taylor MJ
    Parasit Vectors; 2016 Oct; 9(1):532. PubMed ID: 27716391
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease.
    Titus RG; DeKrey GK; Morris RV; Soares MB
    Infect Immun; 2001 Aug; 69(8):5189-92. PubMed ID: 11447205
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reversal of polarized T helper 1 and T helper 2 cell populations in murine leishmaniasis.
    Coffman RL; Correa-Oliviera R; Mocci S
    Ciba Found Symp; 1995; 195():20-5; discussion 25-33. PubMed ID: 8724828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of sand fly saliva in human and experimental leishmaniasis: current insights.
    Andrade BB; de Oliveira CI; Brodskyn CI; Barral A; Barral-Netto M
    Scand J Immunol; 2007; 66(2-3):122-7. PubMed ID: 17635789
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Organ-specific distribution of CD4+ T1/ST2+ Th2 cells in Leishmania major infection.
    Kropf P; Bickle Q; Herath S; Klemenz R; Müller I
    Eur J Immunol; 2002 Sep; 32(9):2450-9. PubMed ID: 12207329
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CTLA4 (CD152) modulates the Th subset response and alters the course of experimental Leishmania major infection.
    Saha B; Chattopadhyay S; Germond R; Harlan DM; Perrin PJ
    Eur J Immunol; 1998 Dec; 28(12):4213-20. PubMed ID: 9862358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-MHC-linked Th2 cell development induced by soluble protein administration predicts susceptibility to Leishmania major infection.
    Guéry JC; Galbiati F; Smiroldo S; Adorini L
    J Immunol; 1997 Sep; 159(5):2147-53. PubMed ID: 9278301
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antigenic diversity in maxadilan, a salivary protein from the sand fly vector of American visceral leishmaniasis.
    Milleron RS; Mutebi JP; Valle S; Montoya A; Yin H; Soong L; Lanzaro GC
    Am J Trop Med Hyg; 2004 Mar; 70(3):286-93. PubMed ID: 15031518
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.
    Tonui WK; Mejia JS; Hochberg L; Mbow ML; Ryan JR; Chan AS; Martin SK; Titus RG
    Infect Immun; 2004 Oct; 72(10):5654-61. PubMed ID: 15385463
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differentiation, regulation, and death of T helper cell subsets during infection with Leishmania major.
    Scott P
    Immunol Res; 1998; 17(1-2):229-38. PubMed ID: 9479584
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.
    Darrah PA; Patel DT; De Luca PM; Lindsay RW; Davey DF; Flynn BJ; Hoff ST; Andersen P; Reed SG; Morris SL; Roederer M; Seder RA
    Nat Med; 2007 Jul; 13(7):843-50. PubMed ID: 17558415
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Requirements for Th1-dependent immunity against infection with Leishmania major.
    von Stebut E; Udey MC
    Microbes Infect; 2004 Oct; 6(12):1102-9. PubMed ID: 15380780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.
    Mattner F; Magram J; Ferrante J; Launois P; Di Padova K; Behin R; Gately MK; Louis JA; Alber G
    Eur J Immunol; 1996 Jul; 26(7):1553-9. PubMed ID: 8766560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development.
    Scott P; Artis D; Uzonna J; Zaph C
    Immunol Rev; 2004 Oct; 201():318-38. PubMed ID: 15361250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The biological and immunomodulatory properties of sand fly saliva and its role in the establishment of Leishmania infections.
    Kamhawi S
    Microbes Infect; 2000 Nov; 2(14):1765-73. PubMed ID: 11137049
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The host response to Leishmania infection.
    Solbach W; Laskay T
    Adv Immunol; 2000; 74():275-317. PubMed ID: 10605608
    [No Abstract]   [Full Text] [Related]  

  • 59. Recent advances in vaccines for leishmaniasis.
    Requena JM; Iborra S; Carrión J; Alonso C; Soto M
    Expert Opin Biol Ther; 2004 Sep; 4(9):1505-17. PubMed ID: 15335317
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Determinant flanking regions and the design of appropriate vaccines.
    Soares L; Deng H; Grewal IS; Kumar V; Miller A; Moudgil KD; Palmer M; Sercarz EE
    Ann N Y Acad Sci; 1995 May; 754():48-56. PubMed ID: 7625680
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.